JP2023138227A - Recycled medical material - Google Patents

Abstract

SOLUTION: The present invention provides biological glass fibers for regenerative medical materials, including biologically active or biologically inactive glasses consisting of glass chemical compositions. A chemical composition of the glass is, in wt.%, 5 to 25 wt.% Na2O, 45 to 67 wt.% SiO2, 15 to 25 wt.% CaO, 2 to 6 wt.% P2O5, 1 to 8 wt.% MgO, and 8 to 12.5 wt.% K2O. Based on 100 wt% of the glass chemical composition, it contains 0.1 to 5 wt.% of group 5A non-toxic elements and groups 3B, 4B, and 5B transition metals in total. Biological glass fiber forms a fiber structure. Biological glass fibers are soluble, absorptive, optically transparent and controllable absorption time regeneration material, the biological glass fiber can mediate therapeutic lymphangiogenesis, stem cell regeneration, bone cell regeneration and neurovascular regeneration and can be used as a cell carrier.SELECTED DRAWING: Figure 1

Description

The present invention relates to biological glass fibers for regenerative medical materials and applications to which they are applied. More specifically, it relates to the invention of biomedical glass fiber compositions made from known biologically biocompatible glass fiber chemical compositions, the fiber compositions being chemically bioabsorbable, optically transparent. , which can mediate lymphangiogenic materials and induce directional placement and proliferation of stem cells. Furthermore, biological glass fibers have the function of mediating stem cell regeneration, bone cell regeneration, neurovascular regeneration, or function as a cell carrier.

Regenerative medicine is the production of functional, vital organs and tissues to repair or replace unhealthy organs and tissues in the body that occur due to aging, disease, or injury. Therefore, developments in the field of regenerative medicine have the potential to stimulate the body's own repair mechanisms to manipulate (generate) damaged tissues and organs and heal previously unrepairable tissues and organs.

In 1969, Dr. Lawrence Hench developed a simple four-component glass for use as a bone replacement material in animals, and more specifically in humans. Eventually, Hench added additional components to this basic glass chemistry, and researchers applying and studying this material family coined the name ``bioglass.'' In recent years, this material has been assigned to a class of materials known as "bioactive glasses" (and therefore biologically compatible glasses).

In recent years, human tissues and organs have been harvested in laboratories for transplantation into patients. Another method involves stimulating the patient's tissues to directly regenerate through drug release within the body. New regenerative medicine technologies are rapidly developing in bone, cartilage, skin, bladder, ureter, kidney, liver, and neuroscience. Careful selection of regeneration materials is important because cells are very sensitive to the physicochemical properties of the culture environment. The mechanical properties and pore structure of the materials used need to be considered, as they influence tissue repair and growth after implantation. The regenerated material has the potential to differentiate into adipocytes, chondrocytes, nerve cells, osteoblasts or muscle cells, depending on the culture conditions or the addition of specific growth factors.

In view of the prior art in this field, the inventors have made innovative advances that overcome the deficiencies of traditional conveyance methods and improve the efficacy and effectiveness of practical recycled materials chemistry. The present invention leverages technology developed for lighting or communications optical fiber manufacturing to bring significantly improved regenerative medical materials to market, fostering industrial development, and providing new approaches to improving the health of society. suggest.

The main object of the present invention is to provide biomedical glass fibers and fiber constructions for regenerative medical materials and their applications.
Single bare fiber configurations or combinatory fiber configurations made from any of the biomedical glass fiber compositions described in this invention generate cellular activation mechanisms, provide cellular needs, and support the immune system. It can provide an internal environment that stimulates integration.
Furthermore, since fiber dissolution and absorption determine functionality, the biomedical glass fibers of the present invention are manufactured with precise structural sizes and specific blending ratios to tune dissolution and absorption rates.
Furthermore, the biomedical glass fibers of the present invention are medical materials used to mediate lymphangiogenesis and induce directional placement and proliferation of stem cells.
Furthermore, with some modification, the derivative has the potential to form a skeleton or neural tube.

To achieve the above objectives, the present invention utilizes the known biological glass family of glass chemical compositions to create fiber-based Manufacture regenerative medical materials.
The glass family composition of biologically active glasses includes 5 to 25 wt% _Na2O , 45 to 67 wt% SiO2, ₁₅ to 25 wt% CaO, and 2 to 25 wt%, based on 100 wt% of the glass chemical composition. Contains 6wt _{% P2O5} .
Here, the biomedical glass fibers form a single bare fiber configuration and/or a hybrid structure fiber configuration.

In embodiments, the glass chemistry of the biomedical glass further includes 1 to 8 wt% MgO and 8 to 12.5 wt% _K2O .

In embodiments, the glass chemistry of the biologically inert glass includes 0.1 to 5 wt% non-toxic Group 5A elements and Groups 3B, 4B and 5B transition metals, based on 100 wt% of the glass chemistry. including.

By applying manufacturing means adapted from well-known textile manufacturing techniques in communication and lighting technology to biological glasses, biomedical glasses can be either single bare fibers or fibers of hybrid structure. .
These biological glass fibers can be solid core or capillary channels.
Additionally, individual fibers can be assembled and combined to form more complex fiber-based structures.

In embodiments, the single bare fiber composition is comprised of bioactive or bioinert glass.

In embodiments, a mixed (hybrid, combination) fiber structure may include, in addition to a single bare fiber structure made of bioactive or bioinert glass.
(1) a single clad fiber made of a core of bioactive glass and an outer cladding of bioinert glass;
(2) a single bare fiber microtube made of bioactive or bioinert glass;
(3) A single hybrid fiber structure with multiple fused internal microtubules made of bioactive or bioinert glass.
(4) A bundle of single bare fibers made of bioactive or bioinert glass in an unfused bundle structure with natural bioglass capillaries in the interstitial spaces.
Natural or natural biological glass capillaries do not mean that they are artificially made glass tubes; for example, when fibers are bundled together, the gaps between the fibers create a capillary function. I want it to be understood as becoming.
(5) A bundle of single bare fiber microtubules in an unfused bundle structure with additional native biological microtubules in the interstitial space.
(6) A bundle of single coated fibers in an unfused structure containing additional native microtubules of bioinert glass in the interstitial space.

In embodiments, the mixed structure fiber configuration is comprised of a single capillary channel fiber configuration (capillary fiber configuration) made of bioactive glass or bioinert glass.

In embodiments, the mixed fiber structure includes a mixed solid fiber configuration, and the hybrid solid fiber configuration is comprised of a bioactive glass, a bioinert glass, and/or a combination of two or more layers thereof.

In embodiments, the mixed fiber structure includes a hybrid single capillary channel fiber configuration (a combination structure of capillary fiber structures), and the hybrid single capillary channel fiber structure (a combination structure of capillary fiber structures) includes a bioactive glass, a bioinert glass, and/or a combination of two or more layers thereof.

In embodiments, the mixed fiber structure comprises a mixed porous microtubular fiber structure, and the mixed porous microtubular (microtubule) fiber structure is comprised of a bioactive glass or a bioinert glass.

In embodiments, the mixed porous microtubule fiber structure is composed of two or more layers of bioactive or bioinert glass and has a circular or non-circular cross-sectional shape.

In embodiments, the single bare fiber structure and the mixed fiber structure include bioinert glass fibers that are opaque to X-rays.
The glass chemistry may also include certain bioactive additive materials to introduce X-ray opacity to one or more bioactive glass fibers to create new structures depending on the type of application.
The glass chemistry may also include certain bioinert additive materials to introduce X-ray opacity to one or more bioinert glass fibers to create new structures depending on the type of application.

In embodiments, creating different absorption times of the regenerated material in the human or animal body for single bare fiber structures and mixed fiber structures by changing the glass chemical composition or changing the diameter size parameters of the fiber components. I can do it.

In embodiments, the single bare fiber configuration has a diameter between 3 and 25 μm.

In embodiments, the hybrid multi-capillary channel fiber configuration (mixed porous microtubule fiber structure) has a circular diameter between 3 and 35 μm.

In embodiments, a hybrid multi-capillary channel fiber configuration (mixed porous microtubule fiber structure) with a non-circular cross-sectional shape has an aperture between 3 and 125 μm.

The main object of the present invention is to provide an application technology of biomedical glass fibers for regenerative medical materials formed from the above-mentioned glass chemical compositions, bioengineered for regenerative medical material devices; it is,
(1) Providing therapeutic lymphangiogenesis;
(2) Directional placement of stem cells and induction of proliferation;
(3) Induction of stem cell regeneration (4) Induction of bone cell regeneration,
(5) Induction of neurovascular regeneration (6) Acting as a cell carrier,
I will provide a.

In embodiments, the composition and use of biomedical glass fibers described above restores macrophages as lymphatic endothelial progenitor cells and promotes drainage of aqueous humor without fibrosis through therapeutic lymphangiogenesis.

In embodiments, biomedical glass fibers can be fabricated to co-culture with dental pulp stem cells (DPSCs), allowing DPSCs to grow towards the biomedical glass fibers within 15 to 18 hours and 22 to 25 hours. Form odontoblasts that grow on biological glass fibers within a few days and form denticles within a few days. Generally, stem cells are defined as undifferentiated cells that exhibit the capacity for self-renewal and multilineage differentiation. In addition to dentinogenic odontoblasts, DPSCs are involved in mesodermal and non-mesoderm tissue cells, including osteoblasts, adipocytes, chondrocytes, myocytes, neurons and endothelial cells, melanocytes, hepatocytes, and retinal stem cells. Can be differentiated.

FIG. 1 is a schematic diagram of a single bare fiber configuration of the present invention. FIG. 2A is a schematic diagram of the fiber composition of the blended structure of the present invention. FIG. 2B is a SEM image of Example 1 for a mixed solid fiber configuration of the present invention. FIG. 2C is a SEM image of Example 2 for a mixed solid fiber configuration of the present invention. FIG. 2D is a SEM image of Example 3 for a mixed solid fiber configuration of the present invention. FIG. 2E is a SEM image of Example 4 for a mixed solid fiber configuration of the present invention. FIG. 2F is a SEM image of Example 5 for a mixed solid fiber configuration of the present invention. FIG. 3A is a photomicrograph image of Example 1 for a single capillary channel fiber configuration of the present invention. FIG. 3B is a photomicrograph image of Example 2 for a single capillary channel fiber configuration of the present invention. FIG. 4A is a photomicrograph image of Example 1 for a mixed single capillary channel fiber configuration of the present invention. FIG. 4B is a photomicrograph image of Example 2 for a mixed single capillary channel fiber configuration of the present invention. FIG. 5A is a photomicrograph image of Example 1 of the tip of a mixed multi-capillary channel fiber configuration (mixed porous microtubule fiber configuration) of the present invention. FIG. 5B is a photomicrograph image of Examples 2 through 12 for a mixed multi-capillary channel fiber configuration (mixed porous microtubule fiber configuration) of the present invention. FIG. 5C is a photomicrograph image of Example 3 for a mixed multi-capillary channel fiber configuration (mixed porous microtubule fiber configuration) of the present invention. FIG. 6 is a photomicrograph image of histopathological examination of cells introduced into the biomedical glass fiber application type of the present invention manipulated with regenerative medical materials for the purpose of mediating lymphangiogenesis. FIG. 7 is a photomicrograph image of histopathological examination of cells introduced into the biomedical glass fiber applied type of the present invention manipulated with regenerative medical material implanted subcutaneously into tissue. FIG. 8 is a photomicrograph image of human dental pulp stem cells (DPSCs) growing in the biological glass fiber application type of the present invention.

In the following paragraphs, a detailed explanation is provided to fully understand the above figures. Well-known structures and devices are also used schematically to enhance understanding.
(Preferred embodiment)

"biologically active glass fiber" (or "bioactive glass fiber"), "biologically-inert glass fiber" (or "biologically inert glass fiber") "), "hybrid biological glass fiber", "biologically active glass fiber with X-ray opacity (bioactive glass fiber)" "glass fiber with X-ray opacity"), "bioinert glass fiber with X-ray opacity" ("bioinert glass fiber with X-ray opacity") The term "biological (or living body or biological use)" as used herein with "use" refers to biological materials that can be applied to living organisms. The term "compatible" means a biological material that can be absorbed by an organism. The term "bioinert" means a biological substance that cannot be absorbed by living organisms, but does not cause harm to them.

Actual example 1
(Example 1)

See FIGS. 1-2F.
FIG. 1 is a schematic diagram of a single bare fiber configuration of the present invention.
FIG. 2A is a schematic diagram of the fiber composition of the blended structure of the present invention.
FIG. 2B is a SEM image of Example 1 for a mixed solid fiber configuration of the present invention.
FIG. 2C is a SEM image of Example 2 for a mixed solid fiber configuration of the present invention.
FIG. 2D is a SEM image of Example 3 for a mixed solid fiber configuration of the present invention.
FIG. 2E is a SEM image of Example 4 for a mixed solid fiber configuration of the present invention.
FIG. 2F is a SEM image of Example 5 for a mixed solid fiber configuration of the present invention.

(Preferred first embodiment)

As shown in Figures 1 to 2F, the present invention provides a bioactive glass (biologically active glass) or a bioinert glass (biologically inert glass) comprising a glass chemical composition for regenerative medical materials. Provides biological glass fibers.
The preferred glass chemical composition of the biological glass of the present invention is 21.5 wt% Na ₂ O, 48.0 wt% SiO ₂ , 24.5 wt% CaO, and 6.0 wt%, with the glass chemical composition being 100 wt%. is P ₂ O ₅ .
Here, the glass chemistry forms a biomedical glass fiber, which is made into a single bare fiber configuration or a hybrid fiber configuration using known techniques. The time required for the recycled glass material to integrate with biological tissues (regenerated chemical absorption time (hereinafter "absorption time")) depends on the chemical composition of the glass.

As shown in Figure 1, a single bare fiber configuration 1 is formed by known melt drawing and microfabrication techniques. As shown in FIG. 2A, a hybrid structure fiber configuration 2 with multiple layers is also formed by melt drawing and microfabrication techniques. The hybrid structure fibrous structure 2 can be composed of two or more layers of biological glass material, and the absorption time of each layer of the hybrid structure fibrous structure 2 can be adjusted to suit the application type.

Alternatively, multiple biological glass compositions are incorporated into a hybrid solid fiber configuration (a mixed solid fiber structure that is solid rather than hollow), as shown in FIGS. 2B to 5C. The shape of biomedical glass fibers can be varied, and the absorption time of each biomedical glass fiber can be varied to suit the type of application. Furthermore, the hybrid fiber structure 2 is a basic component and, depending on the type of application, can be combined and fused to form a hybrid solid fiber structure 20, or a hybrid solid fiber structure 20a, or a hybrid monopore microtubular fiber structure 21, Alternatively, a hybrid porous microtubule fiber structure 22 is formed. Further, the single bare fiber structure 1 has a diameter between 3 and 25 μm, the hybrid solid fiber structure 20 and the hybrid solid fiber structure 20a have a diameter between 3 and 35 μm, and the hybrid monopore microtubule fiber Structure 21, hybrid porous microtubule fiber structure 22 each have a pore size between 3 and 125 μm.

The glass chemical composition of biological glasses for regenerative medical materials forms biological glass fibers (biological glass fibers) that can be used for:
That is,
Providing therapeutic lymphangiogenesis;
directional placement and proliferation induction of stem cells;
induction of stem cell regeneration;
induction of bone cell regeneration,
induction of neurovascular regeneration;
Or it can be used to function as a cell carrier.

The regenerative medical glass materials of the present invention differ from conventional medical polymer materials that rely on degradation or dissociation into small sharp particles prior to slow metabolism. The medical glass material of the present invention dissolves quickly and completely like sugar dissolves in water. Moreover, the regenerative medical material of the present invention is safely and effectively absorbed by the human body. According to the present invention, no foreign matter remains in the body, and undesirable phenomena such as coating of living tissue that occur with other methods do not occur. The patient will not experience any residual discomfort, pathological complications caused as a result of the treatment, and if necessary, the original implant site can be re-treated indefinitely.

(Second embodiment)

The biological _glass composition for regenerative medical materials contains, in weight percentages, 6.5 wt% _Na2O , 50 wt% _SiO2 , 20 wt% CaO, 6 wt% _P2O5 , 6.5 wt% Contains MgO, and 11 wt% _K2O . The biological glass composition is then made into a single bare fiber configuration 1 or a hybrid structured glass fiber configuration 2 by known melt drawing or microfabrication techniques.

Furthermore, the hybrid fiber structure 2 is a basic component and, depending on the type of application, can be combined and fused to form a hybrid solid fiber structure 20, or a hybrid solid fiber structure 20a, or a hybrid monopore microtubular fiber structure 21, Alternatively, a hybrid porous microtubule fiber structure 22 is formed. Further, the single bare fiber structure 1 has a diameter between 3 and 25 μm, the hybrid solid fiber structure 20 and the hybrid solid fiber structure 20a have a diameter between 3 and 35 μm, and the hybrid monopore microtubule fiber Structure 21, hybrid porous microtubule fiber structure 22 each have a pore size between 3 and 125 μm.

The glass chemical composition of biological glass (biograde glass) for regenerative medical materials forms biological glass fibers (biograde glass fiber) that can be used for:
That is,
Providing therapeutic lymphangiogenesis;
directional placement and proliferation induction of stem cells;
induction of stem cell regeneration;
induction of bone cell regeneration,
induction of neurovascular regeneration;
Or it can be used to function as a cell carrier.

As shown in FIGS. 2B to 2F, the hybrid solid fiber configuration 20 includes at least one bioactive (biologically active) glass fiber 201, one bioinert (biologically inert) glass fiber 202, an x-ray opaque or biologically active glass fibers 204 with X-ray opacity. With the known technology of biological glass fiber manufacturing, multiple biological glasses are surrounded by glasses with different refractive index, softening temperature, and coefficient of expansion, thereby making it possible to The surfaces are covered and fused to form a hybrid solid fiber structure 20. The hybrid solid fiber composition 20 is capable of inducing bone cell regeneration, inducing osseointegration of bone tissue, and inducing osteoblast integration.

As shown in FIGS. 2B-2F, the outer layer of the hybrid solid fiber construction 20 is comprised of bioinert glass fibers 202, which is an acid and alkali resistant and insoluble material. The bioinert glass fiber 202 contains trace elements from the transition element group of the periodic table and non-toxic elements from Group 5 (Group 5A). Transition elements include the lanthanides of group 3B, and elements of groups 4B and 5B. As shown in FIG. 2B, the outer layer of the hybrid solid fiber structure 20 is comprised of bioinert glass fibers 202. The core of the hybrid solid fiber structure 20 is composed of bioactive glass fibers 201 and has good light transmittance. And between the outer layer and the center of the hybrid solid fiber structure 20 is a layer of radiopaque bioinert glass fibers 203.

In FIG. 2C, there are three sectors of bioactive glass fiber 201 members within the hybrid solid fiber structure 20, the remainder being bioinert glass fibers 203 containing a biologically inert x-ray opacity additive. , which can be observed with an X-ray camera.
In FIG. 2D, there are five bioactive glass fibers 201 in the hybrid solid fiber configuration 20.
In FIG. 2E, there are seven bioactive glass fibers 201 within the hybrid solid fiber structure 20.
The hybrid solid fiber structure 20 is absorbed to form a groove, which can be used for osseointegration (implant bone-tissue integration), and the rest is radiopaque bioinert glass fiber 203, which is It can be observed with a camera.

As shown in FIGS. 2B to 2E, the hybrid solid fiber structure 20 is composed of bioactive glass fibers 201, bioinert glass fibers 202, and radiopaque bioinert glass fibers 203, all of which Dissolution times vary.
As shown in FIG. 2F, the hybrid solid fiber structure 20a is the same as the hybrid solid fiber structure 20 of FIG. 2E, except that the hybrid solid fiber structure 20a of FIG. It has glass fiber 204.
As shown in FIG. 2F, the biological bioglass fiber 201a is composed of chemical components with improved dissolution rate and can be absorbed by the living body in about 2 to 7 days.
The radiopaque bioactive glass fibers 204 can be bioabsorbed in about 30 days. The bioactive glass fiber 201 is absorbed by the living body in about 65 days.

Bioactive glass fibers 201 induce therapeutic lymphangiogenesis. The purpose of the hybrid solid fiber structure 20 with X-ray opacity is to facilitate X-ray imaging and to facilitate localization of bioactive glass fibers 201 implanted in a living body. Additionally, depending on the type of application, the hybrid solid fiber structures 20 of FIGS. 2B, 2C, and 2D may also be composed of bioglass fibers with different dissolution rates.

From Table 1 below, it can be seen that when other conditions (temperature, pH, liquid medium, fiber diameter, etc.) are equal, the higher the content of SiO2 (silicon dioxide), the slower the dissolution rate and the longer the absorption time of the recycled material. I know what will happen.
The diameter of all biological materials in Table 1 is 15 μm.

Table-1 Substrate glass chemical composition dissolution rate

See Figures 3A-3B.
FIG. 3A is a SEM image of a single capillary channel fiber configuration 23 with a square shaped hybrid core 222 of the present invention.
FIG. 3B is a SEM image of a single capillary channel fiber configuration 23 with an oval shaped hybrid core 222 of the present invention.

See Figures 4A-4B.
FIG. 4A is an SEM image of the present invention for a hybrid single capillary channel fiber configuration 21.
It demonstrates the wide applicability of the hybrid structure of the present invention and demonstrates the diverse types of applications with bioactive and bioinert glass materials as continuous layers.
FIG. 4B is a SEM image of the present invention of a two-layer hybrid single capillary channel fiber configuration.

FIG. 5A is a photomicrograph image of the tip of a hybrid multi-capillary channel fiber configuration of the present invention.

FIG. 5B includes SEM images of possible cross-sectional examples of hybrid multi-capillary channel fiber configurations of the present invention, demonstrating the wide applicability of the hybrid structure. Any of the examples can be used as a drug carrier, and chemicals can be carried in the channels. In treatment, the chemicals needed by the patient are placed in the channels, and the hybrid fiber is placed inside the human or animal body. Once the chemical reaches the treatment site, the chemical is released into the treatment site for treatment. Additionally, the number, shape, and size of capillary holes can be easily modified to accommodate drug release rates, depending on application requirements. Additionally, as shown, the capillary holes can be circular or polygonal, although the invention is not limited thereto.

FIG. 5C is a SEM image of a cross-sectional example of a hybrid multi-capillary channel fiber configuration (hybrid porous microtubule fiber structure) of the present invention, where the hybrid porous microtubule fiber structure 22 as the primary outer cladding is , has multiple fused microtubules consisting of microtubule fibers 221.

lymphangiogenesis test

experimental animals

Eight-week-old New Zealand white rabbits were used in the experiment, and their weight was approximately 2000 to 2500 g. All experimental animals are kept in a separate air-conditioned animal room, room temperature is maintained at 22°C, relative humidity is maintained at 45%, and water and food are provided adequately. Prior to the experiment, experimental animals are given a period of at least 4 weeks to adapt to the environment. Laboratory animal breeding conditions, handling, and all experimental procedures comply with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

The area around the New Zealand White Rabbit's eyes was shaved and disinfected with iodine and 70% alcohol. No. 1, which incorporates an implant with a monofilament structure or a mixed fiber structure into a fiber bundle. A 26 or 27 gauge needle is inserted through the sclera and into the anterior chamber. Maintaining the position of the monofilament or mixed fiber structure implant within the fiber bundle, the 26 or 27 gauge needle is withdrawn, leaving the fiber bundle implant to complete the operation. Please refer to FIG. FIG. 6 is a histopathological cross-sectional image of bioactive glass fibers and new lymph vessels for the regenerative medical material of the present invention engineered with certain regenerative medical materials for the purpose of mediating lymphangiogenesis. As shown in FIG. 6, the red arrow indicates the position of the new lymphatic vessel along the fistula tract. Biological glass fibers revive macrophages as lymphatic endothelial progenitor cells and promote lymphangiogenesis and aqueous humor drainage without fibrosis through therapeutic lymphangiogenesis. After the lymphatic stent is placed in the eye, it begins to drain and is completely resorbed after 3 months, allowing the lymphangiogenic immune system to grow lymphatic vessels. After 7 months, the structure of the lymph vessels changes from thick to thin, and the drainage pressure naturally balances. Lymphatic drainage remained smooth even after 7 months.

The back of a New Zealand White Rabbit was shaved and disinfected with iodine and 70% alcohol. A small opening was cut in the back of the New Zealand White Rabbit with a surgical knife, and biocompatible glass fibers were implanted into the New Zealand White Rabbit in a subcutaneous position.

Table 2 below shows the fiber configuration of the hybrid structure implanted in a subcutaneous location in New Zealand white rabbits. After 12 weeks, the formation of a hybrid fibrous composition with different diameters and lymphatic vessels was observed.

Table 3 below shows the changes in the mixed porous microtubule fiber structure subcutaneously transplanted into New Zealand white rabbits. This mixed porous microtubule fiber structure and lymphangiogenesis with different hole spacings were observed after 12 weeks. Pore spacing (channel distance) refers to the outer spacing (distance) of two mixed porous microtubule fiber structures.

The results in Tables 2-3 provided a histopathological report of the 12-week rabbit subcutaneous implantation study. Referring to FIG. 7, the red circle represents the cross section of the mixed porous microtubule fiber structure. Under appropriate conditions, the mixed porous microtubule fibrous structure promotes therapeutic lymphangiogenic healing in a way that bioactive glass fiber bundles activate macrophage-derived lymphatic endothelial cell progenitor cells and are implanted subcutaneously. The site showed no obvious signs of inflammation, cysts, hemorrhage, necrosis or discoloration.

Please refer to FIG. FIG. 8 is a SEM image of human dental pulp stem cells growing on biologically compatible glass fibers of the present invention.

As shown in Figure 8, biocompatible glass fibers are oriented. When human dental pulp stem cells (hDPSCs) 3 are placed into a single bare fiber configuration or a hybrid structured fiber configuration, the human dental pulp stem cells 3 grow along the bioactive glass fibers 201. Here, the lower left corner of each photograph in FIG. 8 is the time during which human dental pulp stem cells were grown. When bioactive glass fibers 201 are co-cultured with human dental pulp stem cells 3, after 16 hours, human dental pulp stem cells 3 gradually move towards bioactive glass fibers 201. Furthermore, human dental pulp stem cells 3 gradually migrate to bioactive glass fibers 201 after 18 hours. After 22 hours, human dental pulp stem cells 3 have grown onto bioactive glass fibers 201. After 24 hours, human dental pulp stem cells 3 grow onto bioactive glass fibers 201. The situation became more obvious after 48 hours, a large number of human dental pulp stem cells 3 had grown near the bioactive glass fibers 201.

Other biological glass chemical compositions suitable for regenerative medical materials that have already been developed or may be developed in the future include any type of fiber configuration described above for the purpose of introducing said regenerative medical materials into living organisms. may be applicable to The description of each figure above provides a theoretical explanation and its practical application. The embodiments shown above and the accompanying drawings are illustrative and are not intended to be exhaustive or to limit the scope of the disclosure. Modifications and variations are possible in light of the above suggestions.

1 Single bare fiber structure 2 Hybrid fiber structure 20 Hybrid solid fiber structure 201 Bioactive glass fiber 202 Bioinert glass fiber 203 Radiopaque bioinert glass fiber 204 Radiopaque Permeable bioactive glass fiber 20a Mixed solid fiber structure 21 Hybrid single-pore microtubule fiber structure 22 Hybrid porous microtubule fiber structure 221 Microtubule fiber 222 Hybrid core 23 Single-pore microtubule fiber structure 3 Human pulp stem cells

Claims (17)

A biological glass fiber for regenerative medical materials,
comprising a glass chemical composition of bioactive glass or bioinert glass;
The glass chemical composition of bioactive glass is 100 wt% glass chemical composition, 5 to 25 wt% Na ₂ O, 45 to 67 wt% SiO ₂ , 15 to 25 wt% CaO, and 2 to 6 wt% P ₂ O ₅ . including,
Bioactive glass fibers are biological glass fibers characterized in that they form a single bare fiber configuration or a hybrid fiber configuration. The biological glass fiber according to claim 1,
A biological glass fiber characterized in that the glass chemical composition of the bioactive glass further includes 1 to 8 wt% MgO and 8 to 12.5 wt% K ₂ O. The biological glass fiber according to claim 1,
The glass chemical composition of bioinert glass is 100 wt%,
A biological glass fiber characterized by containing 0.1 to 5 wt% of non-toxic elements of group 5A and 3B, 4B and 5B transition metals. The biological glass fiber according to claim 1,
Biomedical glass fiber characterized in that the single bare fiber structure is composed of bioactive or bioinert glass. The biological glass fiber according to claim 1,
A biological glass fiber characterized in that the mixed fiber structure includes a single-pore microtubule fiber structure composed of bioactive glass or bioinert glass. The biological glass fiber according to claim 1,
A biological glass fiber characterized in that the mixed fiber structure further includes a mixed porous microtubule fiber structure composed of a bioactive glass or a bioinert glass. The biological glass fiber according to claim 1,
The biomedical glass fiber is characterized in that the mixed fiber structure further comprises a mixed solid fiber structure comprised of two or more layers of bioactive glass, bioinert glass, or a combination thereof. The biological glass fiber according to claim 1,
the mixed fiber structure has a mixed single microtubule fiber structure;
A biological glass fiber characterized in that the mixed single microtubule fiber structure consists of two or more bioactive glasses, bioinert glasses, or a combination thereof. The biological glass fiber according to claim 6,
The mixed porous microtubule fiber structure is composed of two or more layers of bioactive or bioinert glass;
A biomedical glass fiber characterized by having a circular or non-circular cross-sectional shape. The biological glass fiber according to claim 1,
A biological glass fiber characterized in that the single bare fiber structure or the mixed fiber structure comprises bioinert glass fibers that are opaque to X-rays. The biological glass fiber according to claim 1,
Based on either a change in the chemical composition of the glass or a change in the diameter of the fiber parts,
A biomedical glass fiber, characterized in that the single bare fiber structure or the mixed fiber structure has different regeneration material uptake times in the human or animal organism. The biological glass fiber according to claim 1,
A biological glass fiber characterized in that the single bare fiber structure has a diameter of 3 to 25 μm. The biological glass fiber according to claim 9,
A biological glass fiber characterized in that the mixed porous microtubule fiber structure has a circular diameter of 3 to 35 μm. The biological glass fiber according to claim 9,
A biological glass fiber characterized in that the pore size of the mixed porous microtubule fiber structure having a non-circular cross-sectional shape is 3 to 125 μm. The biological glass fiber for regenerative medical material formed from the glass chemical composition according to claim 1 can be used to induce therapeutic lymphangiogenesis, or to induce directional placement and proliferation of stem cells, or to induce the directional placement and proliferation of stem cells. A biological glass fiber characterized by having a function of regenerating bone cells, inducing regeneration of bone cells, inducing regeneration of nerve blood vessels, or functioning as a cell carrier. The biological glass fiber according to claim 15,
A biological product characterized in that the biological glass fiber activates macrophage-derived lymphatic endothelial cell progenitor cells and promotes lymphangiogenesis and atrial fibrillation through therapeutic lymphangiogenic water drainage without fibrosis. glass fiber. The biological glass fiber according to claim 15,
Biological glass fibers are co-cultured with dental pulp stem cells (DPSCs),
Dental pulp stem cells (DPSCs) grow towards biological glass fibers,
As a result, dental pulp stem cells (DPSCs) grow on the biological glass fiber and integrate into dentin-forming odontoblasts within a clinically useful period.